Sehn L - Search Results

1

FDG-PET is prognostic and predictive for progression-free survival in relapsed follicular lymphoma: exploratory analysis of the GAUSS study.

Kostakoglu L, Goy A, Martinelli G, Caballero D, Crump M, Gaidano G, Baetz T, Buckstein R, Fine G, Fingerle-Rowson G, Berge C, Sahin D, Press O, Sehn L. Kostakoglu L, et al. Among authors: sehn l. Leuk Lymphoma. 2017 Feb;58(2):372-381. doi: 10.1080/10428194.2016.1196815. Epub 2016 Jun 24. Leuk Lymphoma. 2017. PMID: 27339738 Clinical Trial.

2

A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150.

Belch A, Kouroukis CT, Crump M, Sehn L, Gascoyne RD, Klasa R, Powers J, Wright J, Eisenhauer EA. Belch A, et al. Among authors: sehn l. Ann Oncol. 2007 Jan;18(1):116-121. doi: 10.1093/annonc/mdl316. Epub 2006 Sep 13. Ann Oncol. 2007. PMID: 16971665 Free article. Clinical Trial.

3

Treatment of diffuse large B-cell lymphoma: a risk-based approach.

Sehn LH, Connors JM. Sehn LH, et al. Clin Lymphoma Myeloma. 2006 Oct;7 Suppl 1:S14-9. doi: 10.3816/clm.2006.s.003. Clin Lymphoma Myeloma. 2006. PMID: 17101068 Review.

4

The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP.

Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, Klasa R, Savage KJ, Shenkier T, Sutherland J, Gascoyne RD, Connors JM. Sehn LH, et al. Blood. 2007 Mar 1;109(5):1857-61. doi: 10.1182/blood-2006-08-038257. Epub 2006 Nov 14. Blood. 2007. PMID: 17105812 Free article.

5

CHOP-R therapy overcomes the adverse prognostic influence of BCL-2 expression in diffuse large B-cell lymphoma.

Wilson KS, Sehn LH, Berry B, Chhanabhai M, Fitzgerald CA, Gill KK, Klasa R, Skinnider B, Sutherland J, Connors JM, Gascoyne RD. Wilson KS, et al. Leuk Lymphoma. 2007 Jun;48(6):1102-9. doi: 10.1080/10428190701344881. Leuk Lymphoma. 2007. PMID: 17577773

6

Alemtuzumab in clinical practice: a British Columbia experience.

Hui D, Lam W, Toze C, Delorme M, Noble M, Klimo P, Sutherland J, Gill K, Connors J, Sehn L. Hui D, et al. Among authors: sehn l. Leuk Lymphoma. 2008 Feb;49(2):218-26. doi: 10.1080/10428190701760029. Leuk Lymphoma. 2008. PMID: 18231907

7

Early detection of patients with poor risk diffuse large B-cell lymphoma.

Sehn LH. Sehn LH. Leuk Lymphoma. 2009 Nov;50(11):1744-7. doi: 10.3109/10428190903308064. Leuk Lymphoma. 2009. PMID: 19860615 Review.

8

Prognostic factors in follicular lymphoma.

Relander T, Johnson NA, Farinha P, Connors JM, Sehn LH, Gascoyne RD. Relander T, et al. J Clin Oncol. 2010 Jun 10;28(17):2902-13. doi: 10.1200/JCO.2009.26.1693. Epub 2010 Apr 12. J Clin Oncol. 2010. PMID: 20385990 Review.

9

The value of positron emission tomography in prognosis and response assessment in non-Hodgkin lymphoma.

Dunleavy K, Mikhaeel G, Sehn LH, Hicks RJ, Wilson WH. Dunleavy K, et al. Leuk Lymphoma. 2010 Aug;51 Suppl 1:28-33. doi: 10.3109/10428194.2010.500051. Leuk Lymphoma. 2010. PMID: 20658958 Review.

10

Prognostic implications of extranodal involvement in patients with diffuse large B-cell lymphoma treated with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone.

Hui D, Proctor B, Donaldson J, Shenkier T, Hoskins P, Klasa R, Savage K, Chhanabhai M, Gascoyne RD, Connors JM, Sehn LH. Hui D, et al. Leuk Lymphoma. 2010 Sep;51(9):1658-67. doi: 10.3109/10428194.2010.504872. Leuk Lymphoma. 2010. PMID: 20795790

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

250 results

Search Page